Scientists at Stanford University have developed a liquid biopsy technique that analyzes cell-free RNA in urine to detect bladder cancer and monitor patients for residual cancer cells after treatment. The test achieved an approximate 95% sensitivity rate in validation models, according to findings published in Nature Medicine.
Bladder cancer carries a risk of recurrence, requiring patients to undergo regular cystoscopy procedures to confirm if tumors have reappeared. To ease this physical and psychological burden, the Stanford research team investigated whether genetic material shed by tumors into urine could serve as a non-invasive tracking tool.
Researchers Isolate Cell-Free RNA Fragments from Urine
Cell-free RNA consists of ribonucleic acid fragments that float freely outside intact cells in bodily fluids. Because urine naturally contains very low quantities of these molecules and they degrade easily, isolating and sequencing them historically presented a major technical hurdle. The research team overcame this obstacle by capturing these fragile, short RNA segments and performing genetic sequencing across thousands of genes.
When analyzing healthy subjects, investigators found that urinary cell-free RNA originated primarily from normal tissues of the kidneys, prostate, and bladder. In contrast, patients with bladder cancer exhibited gene expression patterns that closely mirrored tumor tissue. This performance surpasses standard urine cytology and outperforms some existing tests based on urinary tumor DNA.
Urine Tests Detect Bladder Cancer with High Sensitivity
- Liquid Biopsy Alternative: The test uses a simple urine sample instead of invasive cameras to scan for molecular signs of cancer.
- High Sensitivity: The method successfully detected about 95% of localized bladder cancer cases in validation testing, outperforming traditional urine cell analysis.
- Early Warning Potential: By tracking RNA levels after treatment, doctors may spot returning cancer cells before they are detected by imaging or general examinations.
Beyond initial detection, the researchers tracked 36 patients undergoing treatment for bladder cancer to evaluate whether the RNA signatures could monitor therapeutic success. Prior to surgical intervention, cancer-associated RNA was detected in every patient’s urine sample. Following treatment, these specific RNA signals steadily declined and disappeared in patients who did not have a recurrence. Conversely, most patients who later experienced highly malignant recurrence maintained detectable cancer-associated RNA levels post-treatment.
| Clinical Parameter | Study Finding |
|---|---|
| Validation Sensitivity | ~95% for localized bladder cancer detection |
| False-Positive Rate | ~10% in healthy control subjects |
| Patient Cohort (Longitudinal) | 36 patients tracked post-treatment |
| Treatment Response Model | Evaluated across 114 patient datasets |
The research team established a predictive model using data from 114 patients to forecast therapeutic outcomes. The model successfully differentiated between patients who responded favorably to treatment and those with poor outcomes, with predictions strongly correlating with subsequent recurrence risks. In the future, oncologists could potentially integrate urinary cell-free RNA results alongside traditional tumor size and pathological grading to adjust treatment strategies.
Cystoscopy Remains the Standard for Confirming Tumors
Standard diagnostic workflows, including cystoscopy, remain the method for confirming if tumors have reappeared in the bladder. Urinary RNA assays are still in the research phase.
The transition from experimental sequencing models to routine clinical practice requires overcoming hurdles. As laboratory techniques advance and become simpler and cheaper, researchers aim to provide more cancer-related information through a standard urine collection.
References
- Stanford University. Research on urinary cell-free RNA sequencing. Published in Nature Medicine.
- TechNews 科技新報. Reporting on Stanford University’s liquid biopsy study for bladder cancer detection.
Worth a look
